Treatment News : Hep C Treatment Telaprevir Gets Fast-Tracked FDA Review

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » January 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

January 21, 2011

Hep C Treatment Telaprevir Gets Fast-Tracked FDA Review

Vertex Pharmaceuticals announced on January 20 that the U.S. Food and Drug Administration (FDA) has agreed to expedite its approval review of the experimental hepatitis C protease inhibitor telaprevir. The agency has until May 23—six months from the original New Drug Application (NDA) filing date of November 23—to complete its review. 

Vertex also announced the completion of a New Drug Submission (NDS) to the Therapeutic Product Directorate (TPD) of Health Canada seeking approval for telaprevir in Canada, where it was also granted Priority Review.

The U.S. NDA and Canadian NDS are supported by results from three Phase III studies evaluating the protease inhibitor in people chronically infected with genotype 1 hepatitis C virus (HCV) who were new to treatment as well as those who were treated before but did not achieve a sustained virologic response (SVR, or viral cure).

All Phase III studies, in which telaprevir was started immediately in combination with standard HCV treatment (pegylated interferon plus ribavirin) for the first 12 weeks of treatment, met their primary objectives.

In people with hepatitis C who were new to treatment, up to 75 percent achieved an SVR with telaprevir-based combination therapy, compared with 44 percent of people who received pegylated interferon and ribavirin alone. What’s more, a majority of patients treated with telaprevir in the treatment-naive studies (ADVANCE and ILLUMINATE) were eligible to reduce their treatment time by half—from 48 to 24 weeks.

Among those who had not achieved an SVR with an earlier course of treatment, SVRs were significantly more likely to be documented upon retreatment with the addition of telaprevir, compared with those retreated with pegylated interferon and ribavirin alone.

Standard review in the United States takes about 10 months. Priority Review shortens the review time to six months. And in Canada, where standard review can take at least 18 months, Priority Review results in an approval decision from TPD within six to nine months.

Vertex is developing telaprevir in collaboration with Tibotec Pharmaceuticals and Mitsubishi Tanabe Pharma. Vertex has rights to commercialize telaprevir in North America, and Tibotec has rights in Europe, South America, Australia, the Middle East and certain other countries. Mitsubishi Tanabe Pharma has rights to commercialize telaprevir in Japan and certain Far East countries.

Search: Vertex, telaprevir, new drug application, priority review, approval, protease inhibitor, hepatitis C


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (2 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dave41
    Bethany
    Oklahoma


    july8th69
    brooklyn
    New York


    hollywoodvers1
    Los Angeles
    California


    humboman
    Baltimore
    Maryland
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.